How can patient covariates such as weight and renal function contribute to interindividual PK variability?

• A. They affect clearance and distribution; weight is used in allometric scaling, and renal function directly influences renal clearance.
• B. They do not influence PK; only dose matters.
• C. Weight affects only distribution; renal function affects only metabolism.
• D. Only age and gender influence PK.

Answer: (A)

The main idea is that patient-specific factors like body size and kidney function can change how a drug behaves in the body, contributing to differences between individuals. Weight matters because it influences both the volume where the drug distributes and the rate at which it is cleared; in pharmacokinetics, body weight is incorporated through allometric relationships to predict clearance and volume of distribution across different people. Renal function directly affects how quickly many drugs are eliminated, since the kidneys are a major route of clearance; reduced renal function lowers renal clearance and can raise drug exposure. Together, these covariates help explain interindividual PK variability and why dosing may need to account for body size and renal status. Other options are too narrow or incomplete: weight does not affect only distribution, and renal function is not limited to metabolism; and age or gender are not the only factors that influence PK.